- Home
- ALTI vs MNPR Comparison
ALTI vs MNPR Comparison
Compare ALTI & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ALTI | MNPR |
|---|---|---|
| Founded | 2020 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 394.0M | 372.9M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ALTI | MNPR |
|---|---|---|
| Price | $3.73 | $57.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $101.42 |
| AVG Volume (30 Days) | 94.9K | ★ 150.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 41.11 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $206,935,000.00 | N/A |
| Revenue This Year | $19.78 | N/A |
| Revenue Next Year | $7.00 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.33 | $26.06 |
| 52 Week High | $5.45 | $105.00 |
Technical Indicators
Market Signals| Indicator | ALTI | MNPR |
|---|---|---|
| Relative Strength Index (RSI) | 28.49 | 48.74 |
| Support Level | $3.31 | $56.15 |
| Resistance Level | $4.39 | $61.30 |
| Average True Range (ATR) | 0.25 | 3.36 |
| MACD | -0.08 | 0.83 |
| Stochastic Oscillator | 10.06 | 65.33 |
Price Performance
Historical ComparisonAbout ALTI AlTi Global Inc.
AlTi Global Inc is an independent wealth and asset manager providing entrepreneurs, multi-generational families, institutions, and emerging next-generation leaders with fiduciary capabilities as well as alternative investment strategies and advisory services. The firm has business which is organized into two business segments namely: Wealth & Capital Solutions and the International Real Estate segment includes providing holistic solutions for wealth management clients through comprehensive range of wealth management services, including investment management and advisory services. International Real Estate segment includes assist investors with real estate co-investments, structuring and selecting partners with a track record with risk adjusted return characteristics.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.